Jak2 targeting for therapies

[EPguy]

We've had posts on promising immune therapies for CALR. These take advantage of the fact that CALR is findable in the body. A related item is the resistance of Jak2 being discovered and thus a barrier to immune therapies for Jak2.

Here is a very technical report I don't understand, but I believe it's part of efforts to make Jak2 discoverable. I think they mean using JH2 as a way to get at Jak2 mutations.

More broadly it's an example of efforts with the basics to get better Jak2 targeted therapies. These efforts, if we're lucky, end up years later in our bodies fixing things.

pubs.acs.org/doi/10.1021/ac...

<< V617F mutation in JH2 has been associated with the pathogenesis of various myeloproliferative neoplasms, but JAK2 JH2 has been poorly explored as a pharmacological target.... we optimized a... compound into potent, selective, and cell-permeable JH2 binders>> (as a way to nail Jak2.)

[MPort]

Great to know there is research going on and thanks for posting.

[MPNBlog]

Hi EP GuyThanks for posting. This article shows how necessary it is for MPN specialists and biological researchers to work together to find solutions for us. Haems tend to focus on preventing thrombotic events and prolonging progression free survival. But we want more. If we are to get a cure, it will come from research like this. So those interested in MPNs need to work together more. I am somewhat despondent that we MPNers aren't a large enough cohort for drug companies to sell their products to that will justify their research costs; and for the same reason, MPN research results don't get university researchers any brownie points. So we end up using off label drugs. But the rate of research has improved in recent years, mainly since MPNs were classified as cancers. We can only hope. Best wishes.

[EPguy in reply to MPNBlog]

Getting clinical world to consider the possibility to improve progression is itself progress; 5 years ago this idea was an outlier. Reversing it is our latest hope, some of the top MPN Drs are getting on board. But INF, a key solution lately, is not a cure, we need to advance as Hep C did, from INF to a magic pill. In the meantime, our best hope I think will be INF + (something), same as Hep C had.

In a recent post it was noted that here are 1000+ MPN studies going on now, most in the US. I can't find that post unfortunately. I had noted the work here could be a benefit of our overpriced drug system. All this activity is likely from that Cancer designation as you say.